Only two types of medications have been proved to slow the cognitive decline associated with Alzheimer's.
By Bob DeMarco
Alzheimer's Reading Room
Treatment for Mild to Moderate Alzheimer’s
Cholinesterase inhibitors
Medications called cholinesterase inhibitors are prescribed for mild to moderate Alzheimer’s disease. These drugs may help delay or prevent symptoms from becoming worse for a limited time and may help control some behavioral symptoms.
This group of medications which includes:
- Aricept (donepezil)
- Exelon (rivastigmine>
- and Razadyne(galantamine)
Scientists do not yet fully understand how cholinesterase inhibitors work to treat Alzheimer’s disease, but research indicates that they prevent the breakdown of acetylcholine, a brain chemical believed to be important for memory and thinking. As Alzheimer’s progresses, the brain produces less and less acetylcholine; therefore, cholinesterase inhibitors may eventually lose their effect.
No published study directly compares these drugs. Because they work in a similar way, switching from one of these drugs to another probably will not produce significantly different results. However, an Alzheimer’s patient may respond better to one drug than another.
Treatment for Moderate to Severe Alzheimer’s
The first drug approved to treat moderate to severe stages of Alzheimer's, Namenda (memantine) protects brain cells from damage caused by the chemical messenger glutamate.
Namenda's main effect is to delay progression of some of the symptoms of moderate to severe Alzheimer’s. It may allow patients to maintain certain daily functions longer than they would without the medication. For example, Namenda may help a patient in the later stages of the disease maintain his or her ability to use the bathroom independently for several more months, a benefit for both patients and caregivers.
Namenda is believed to work by regulating glutamate, an important brain chemical. When produced in excessive amounts, glutamate may lead to brain cell death. Because NMDA antagonists work very differently from cholinesterase inhibitors, the two types of drugs can be prescribed in combination.
Namenda is often used in combination with a cholinesterase inhibitor. Memantine's most common side effect is dizziness, although it also appears to increase agitation and delusional behavior in some people.
The Combination of Aricept and Namenda Helps Slow the Rate of Decline in Alzheimer's Patients
The FDA has also approved Aricept® for the treatment of moderate to severe Alzheimer’s disease.
There are a long list of experimental drugs that are currently being tested for the treatment of Alzheimer's disease. These include:
Dimebon
Bapineuzumab (several studies)
Immune Globulin Intravenous (IGIV)
Varenicline
CERE-110
For a complete list of all ongoing clinical trials for Alzheimer's disease go to Clinical Trials.gov
For a more comprehensive description of Alzheimer's disease including: symptoms, causes, treatments, drugs, testing and diagnosis go here.
Also see
Test Your Memory for Alzheimer's (5 Best Self Assessment Tests)
- What’s the Difference Between Alzheimer’s Disease and Dementia
- How the Loss of Memory Works in Alzheimer’s Disease, and How Understanding This Could Help You
- Learning How to Communicate with Someone Suffering From Alzheimer's Disease
- What is Alzheimer's Disease?
- What is Dementia?
- Alzheimer's World -- Trying to Reconnect with Someone Suffering from Alzheimer's Disease
- Urinary Tract Infections, Urinary Incontinence, Poop (8 Articles)
- Generic Aricept (Donepezil) Clarification
- Alzheimer's Disease, Types of Dementia, and What is the Difference Between Alzheimer's and Dementia
- What Was the First Sign of Alzheimer's Disease in Your Case?
- Alzheimer's Disease and the Five Stages of Grief
- Alzheimer's Disease Caregiving Advice and Insight (20 articles)
- Test Your Memory for Alzheimer's Disease (5 Best Self Assessment Tests)
- Alzheimer's Disease Statistics
- Alzheimer's Disease and Driving
- Alzheimer's Caregiving Dealing with Behavior
- Alzheimer's Disease -- The Front Row
- The Plan to End Alzheimer's Disease by 2020 (Podcast)
Bob DeMarco is the Founder of the Alzheimer's Reading Room and an X Wall Street executive turned full time Alzheimer's caregiver. The blog contains more than 2,310 articles with more than 285,100 links on the Internet. Bob resides in Delray Beach, FL.Original content Bob DeMarco, the Alzheimer's Reading Room

